Stocks Hitting 52-Week Lows

Sarepta Therapeutics Inc SRPT shares touched a new 52-week low of $9.23 after a federal advisory panel voted that eteplirsen, its drug for the treatment of Duchenne muscular dystrophy (DMD), was not effective. The U.S. Food and Drug Administration voted 6-7 against the finding of substantial evidence that eteplirsen induces production of dystrophin to a level that is reasonably likely to predict clinical benefit. Active Power, Inc. ACPW shares dropped 34.31 percent to touch a new 52-week low of $0.670. Active Power reported a Q1 loss of $0.18 per share on revenue of $5.7 million. First Acceptance Corporation FAC shares fell 6.51 percent to reach a new 52-week low of $1.58. First Acceptance shares have tumbled 41.72 percent over the past 52 weeks, while the S&P 500 index has declined 1.28 percent in the same period. Catalyst Pharmaceuticals Inc CPRX shares dropped 53.63 percent to touch a new 52-week low of $0.575 as the company issued a regulatory update on Firdapse. Piper Jaffray downgraded Catalyst Pharmaceuticals from Overweight to Neutral.